Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.52 |
| ▸ | CDK2 | P24941 | 6/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25210520 | 0.82 | MAPT (0.56) | MAPTMEN1KMT2APOLBCCNA2 | |
| SCHEMBL25200708 | 0.82 | MAPT (0.60) | MAPTMEN1KMT2APOLBCCNA2 | |
| SCHEMBL23930511 | 0.82 | CCNA2 (0.60) | MAPTMEN1KMT2APOLBCCNA2 | |
| SCHEMBL25217024 | 0.80 | CCNA2 (0.62) | MAPTMEN1KMT2APOLBCCNA2 | |
| SCHEMBL23956843 | 0.80 | MAPT (0.56) | MAPTMEN1KMT2APOLBCCNA2 | |
| SCHEMBL25198518 | 0.80 | CDK5 (0.62) | MAPTMEN1KMT2APOLBCCNA2 | |
| SCHEMBL25194165 | 0.79 | CDK5 (0.59) | MAPTMEN1KMT2APOLBCCNA2 | |
| SCHEMBL23930463 | 0.79 | MAPT (0.57) | MAPTMEN1KMT2APOLBCCNA2 | |
| SCHEMBL30210952 | 0.79 | PSMB8 (0.35) | MAPTMEN1KMT2APOLBCCNA2 | |
| SCHEMBL23930647 | 0.78 | MEN1 (0.55) | MAPTMEN1KMT2APOLBCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139287-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| EP-4139287-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115697979-A | Substituted aminothiazoles as DGKZETA inhibitors for immune activation | 拜耳公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021214020-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | MAPT 3251/4885MEN1 4290/4885KMT2A 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.